Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry

Piper Sandler analysts foresee a path to growth for Bristol-Myers Squibb Company (BMY) following the expiry of its Eliquis patent, suggesting new opportunities for the pharmaceutical firm.